Related Experiment Video
Updated: Jul 12, 2025

Author Spotlight: Advancements in Understanding and Combatting Shigella Infections
Published on: February 9, 2024
Trends in antimicrobial resistance of Shigella species in Peru, 2011-2020
Willi Quino1, Gustavo Bellido1, Diana Flores-León1,2
1Laboratorio de Referencia Nacional de Bacteriología Clínica, Instituto Nacional de Salud, Lima, Perú.
Objective:
To describe the frequency of antimicrobial resistance rates and spatial-temporal distribution of Shigella species from the last 10 years in Peru.
Methods:
A cross-sectional descriptive study was carried out. A total of 1668 Shigella strains, remitted as part of the national enteric pathogen surveillance from 2011 to 2020, were analysed. The strains were confirmed by conventional tests and serotyped with polyvalent and monovalent antibodies. Also, antimicrobial susceptibility was performed according to the Kirby-Bauer method.
Results:
The most frequent Shigella species was S. sonnei (49.2%), followed by S. flexneri (42.2%), S. boydii (7.9%) and S. dysenteriae (0.7%). Phase II (46.29%) was the most frequent serotype in S. sonnei, serotype 2a (43.61%) in S. flexneri, serotype 2 in S. boydii and serotype 4 in S. dysenteriae. High rates of resistance were detected for trimethoprim/sulfamethoxazole (91.0%), tetracycline (88.4%), ampicillin (73.9%) and chloramphenicol (64.9%), moderate rates for amoxicillin/clavulanic acid (25.1%), ciprofloxacin (16.7%) and nalidixic acid (14.8%), and low rates for cefotaxime (1.74%), nitrofurantoin (0.7%) and ceftazidime (0.6%). Moreover, antimicrobial resistance to fluoroquinolones increased considerably from 2017 to 2020.
Conclusion:
S. sonnei was the most frequent species, which have a large proportion of strains resistant to trimethoprim/sulfamethoxazole, and a growing trend of resistance to ciprofloxacin and nalidixic acid. This increase in resistance to commonly used antibiotics in treatments is alarming, threatening the control and management of these currently treatable infections.
Insights
Antimicrobial resistance in Shigella species in Peru is high, particularly for trimethoprim/sulfamethoxazole and tetracycline. Resistance to fluoroquinolones like ciprofloxacin is increasing, posing a threat to treating Shigella infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Public Health
Background:
- Shigella species are a major cause of bacterial dysentery worldwide.
- Antimicrobial resistance in Shigella poses a significant public health threat, complicating treatment and increasing morbidity and mortality.
- Understanding the trends of antimicrobial resistance is crucial for effective treatment strategies and disease control.
Purpose of the Study:
- To determine the frequency of antimicrobial resistance rates in Shigella species.
- To analyze the spatial-temporal distribution of Shigella species over a 10-year period in Peru.
- To identify trends in antimicrobial resistance patterns for effective public health interventions.
Main Methods:
- A cross-sectional descriptive study analyzed 1668 Shigella strains from 2011-2020.
- Strains were confirmed using conventional tests and serotyped.
- Antimicrobial susceptibility testing was performed using the Kirby-Bauer method.
Main Results:
- Shigella sonnei (49.2%) was the most frequent species, followed by S. flexneri (42.2%).
- High resistance rates were observed for trimethoprim/sulfamethoxazole (91.0%), tetracycline (88.4%), and ampicillin (73.9%).
- A significant increase in antimicrobial resistance to fluoroquinolones, including ciprofloxacin, was noted from 2017 to 2020.
Conclusions:
- Shigella sonnei is the predominant species, exhibiting high resistance to trimethoprim/sulfamethoxazole.
- The growing resistance to fluoroquinolones and other commonly used antibiotics is alarming.
- Urgent interventions are needed to combat rising antimicrobial resistance and manage Shigella infections effectively.
More Related Videos
Related Concept Videos
Development of Antibiotic Resistance
Antimicrobial Effectiveness
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

